Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

Healthy Clinical Trial

Official title:

Phase 1, Open Label Dose-Finding Study of Intranasal Insulin in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05062785
• Other study ID #: HUM00171279
• Status: Completed
• Phase: Phase 1
• Start date: October 4, 2021
• Est. completion date: April 25, 2022

Study information

• Verified date: October 2022
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to determine the safety and tolerability of regular insulin (Humulin R) when given intranasally (as drops in nostrils). Healthy participants will be enrolled to determine the maximum tolerated dose of intranasal insulin.

Description:

This is being studied because intranasal insulin may be a way to prevent the brain injury that occurs after a cardiac arrest. Cardiac arrest is a life-threatening condition in which the heart suddenly stops beating and there is no blood flow to the body. If cardiac arrest is not treated immediately, it causes sudden death. Even when immediate treatment gets the heart beating again, many victims remain comatose and die later from brain injury. Nasal insulin, given immediately after a cardiac arrest may prevent or reduce brain injury. Nasal insulin reduces brain injury in animal experiments, and has been used to try to improve brain degeneration in patients with Alzheimer's disease. However, cardiac arrest patients may need higher doses than patients with Alzheimer's disease, therefore, this study is to examine those higher doses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: April 25, 2022
• Est. primary completion date: April 25, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Good health based on medical history, physical exam, and routine laboratory testing.
• Female participants must have negative urine pregnancy test or be surgically sterilized or postmenopausal. Criteria for menopause are surgical menopause (hysterectomy, oophorectomy) or age > 45 years with the absence of menses for greater than 12 months. Tubal ligation with menses within the past 12 months is not considered to be surgical sterilization.
• Body mass index (BMI) between 18 kilogram / square meter (kg/m2) and 35 kg/m2.
• Willing and able to stay at the clinical research facility as required by the protocol
• Willing and able to comply with the investigational nature of the study and able to communicate well with investigators
• Ability to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines

Exclusion Criteria:

• Known allergy to insulin.
• Preexisting diabetes.
• Current or previous use of diabetes medication or insulin.
• Any nasal disease or congestion that may interfere with intranasal drug absorption.
• Baseline hypoglycemia (blood glucose = 65 mg/dL) or hyperglycemia (blood glucose > 200 mg/dL) as evident from the screening labs.
• Active serious disease, such as liver disease, kidney disease, uncontrolled hypertension, clinically significant hypokalemia, and significant or unstable medical illness
• Blood donation in excess of 500 milliliter (mL) within 60 days prior to the first dose of study medication.
• Treated with an investigational drug within 30 days.
• Individuals with inadequate venous access.

Related Conditions & MeSH terms

• Healthy
• Out-Of-Hospital Cardiac Arrest

Intervention

Drug:
• Intranasal insulin
This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits. On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
Robert Silbergleit	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severe Hypoglycemia as defined by blood glucose < 45 milligrams per deciliter (mg/dL)	Severe Hypoglycemia will be considered a dose limiting toxicity (DLT).	Up to 4 hours after drug administration
Secondary	Change in blood glucose		Baseline, up to 4 hours after drug administration
Secondary	Change in serum insulin		Baseline, up to 4 hours after drug administration
Secondary	Change in serum C-peptide levels		Baseline, up to 4 hours after drug administration